PSA Screening: What Every Man Should Know

Prostate cancer is the most common non-skin cancer in American men, with approximately 1 in 8 men diagnosed during their lifetime. The prostate-specific antigen (PSA) blood test has been a cornerstone of prostate cancer screening for decades—but it has also been one of the most debated topics in medicine. Here's what you need to know to make an informed decision.

What Is PSA?

PSA is a protein produced by both normal and cancerous prostate cells. A simple blood test measures the level of PSA in your bloodstream. While elevated PSA levels can indicate prostate cancer, they can also be caused by benign conditions such as benign prostatic hyperplasia (BPH), prostatitis (inflammation), urinary tract infections, or even recent vigorous exercise.

The Screening Debate

PSA screening has undoubtedly helped detect prostate cancers at earlier, more treatable stages. However, it has also led to overdiagnosis—identifying slow-growing cancers that may never cause symptoms or threaten life. Overdiagnosis can lead to unnecessary biopsies and treatments with significant side effects, including urinary incontinence and erectile dysfunction.

Major medical organizations now recommend shared decision-making—a conversation between patient and doctor about the potential benefits and risks of screening, tailored to individual risk factors.

Current Guidelines

The American Urological Association (AUA) recommends the following approach:

• Under 40: Routine screening is not recommended.
• Ages 40–54: Screening is recommended for high-risk individuals (African American men, those with a family history of prostate cancer, or known BRCA2 carriers).
• Ages 55–69: Shared decision-making is recommended. This is the age group where screening has the clearest potential benefit.
• 70 and older: Routine screening is generally not recommended, though it may be considered for very healthy men with a long life expectancy.

Beyond PSA: Advanced Diagnostics

If your PSA is elevated, it no longer means an automatic biopsy. Today, we have sophisticated tools to refine risk assessment:

• PSA density and velocity: How PSA relates to prostate size and how quickly it changes over time.
• Free PSA ratio: A lower percentage of free PSA may indicate higher cancer risk.
• Biomarker tests: Tests like the 4Kscore, PHI (Prostate Health Index), and SelectMDx can help determine who truly needs a biopsy.
• MRI-guided biopsy: Multiparametric MRI (mpMRI) can identify suspicious lesions before biopsy, enabling targeted sampling and reducing unnecessary procedures.

The Bottom Line

PSA screening is not a one-size-fits-all decision. The key is having an informed conversation with your urologist about your personal risk factors, values, and preferences. Early detection saves lives—but smart, personalized screening is the goal. If you have questions about whether PSA screening is right for you, I encourage you to schedule a consultation.